BeOne Medicines (BEIGF) Current Deferred Revenue (2015 - 2023)

BeOne Medicines (BEIGF) has reported Current Deferred Revenue for 8 consecutive years, with $159.0 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Current Deferred Revenue fell 2.67% year-over-year to $159.0 million in Q2 2023; TTM through Jun 2023 was $159.0 million, a 2.67% decrease from a year earlier, with the FY2022 full-year figure at $213.9 million, up 14.11% from the prior year.
• Current Deferred Revenue was $159.0 million for Q2 2023 at BeOne Medicines, down from $185.5 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $213.9 million in Q4 2022 and troughed at $17.5 million in Q1 2019.
• A 4-year average of $131.2 million and a median of $159.0 million in 2023 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 156.89% in 2022 and dropped 2.67% in 2023, its largest moves.
• Over 4 years, Current Deferred Revenue stood at $17.5 million in 2019, then soared by 970.69% to $187.4 million in 2021, then gained by 14.11% to $213.9 million in 2022, then fell by 25.64% to $159.0 million in 2023.
• The last three Current Deferred Revenue figures came in at $159.0 million (Q2 2023), $185.5 million (Q1 2023), and $213.9 million (Q4 2022), per Business Quant data.